In pharma tax probe, Wyden puts Pfizer in hot seat with CEO letter
Three years into a Senate Finance Committee investigation into Big Pharma’s tax strategies, committee Chair Ron Wyden, D-Oregon, has set his sights on Pfizer. By sending a letter to Pfizer CEO Albert Bourla, Ph.D., Wyden hopes to learn more about the tax …